As strains of bacteria evolve to fight back against common antibiotics, a slew of biotechnology companies are working to develop ways to combat these “superbugs.”
San Diego’s Forge Therapeutics is among those targeting gram-negative bacteria, a type of bacteria that has a protective outer membrane that makes it especially resistant to drugs. Comparatively, gram-positive bacteria don’t have that extra membrane, and they’re easier to treat.
On Thursday, Forge announced it had been granted $5.7 million by public-private partnership CARB-X to evaluate treatments for serious lung infections caused by gram-negative bacteria, including multi-drug resistant P. aeruginosa, which the Centers for Disease Control… Read more »
UNDERWRITERS AND PARTNERS